Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Shaping the future of cardiometabolic innovation: advances and opportunities

Nature Metabolism volume 7, pages 1495–1497 (2025)Cite this article

Subjects

Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides our views on recent breakthroughs, emerging innovations and future needs of therapeutic interventions to counteract obesity and its associated health risks.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Current and next-generation therapeutics for cardiometabolic diseases.

References

  1. Müller, T. D., Blüher, M., Tschöp, M. H. & DiMarchi, R. D. Nat. Rev. Drug Discov. 21, 201–223 (2022).

    Article  PubMed  Google Scholar 

  2. Petersen, J., Ingemann Johansen, V. B. & Clemmensen, C. Cell Metab. 37, 790–790.e1 (2025).

    Article  CAS  PubMed  Google Scholar 

  3. Jastreboff, A. M. et al. N. Engl. J. Med. 387, 205–216 (2022).

    Article  CAS  PubMed  Google Scholar 

  4. Aronne, L. J. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2416394 (2025).

    Article  PubMed  Google Scholar 

  5. Borner, T. et al. Diabetes 70, 2545–2553 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Finan, B. et al. Nat. Med. 21, 27–36 (2015).

    Article  CAS  PubMed  Google Scholar 

  7. Jastreboff, A. M. et al. N. Engl. J. Med. 389, 514–526 (2023).

    Article  CAS  PubMed  Google Scholar 

  8. Trevaskis, J. L. et al. PLoS ONE 8, e78154 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kruse, T. et al. J. Med. Chem. 64, 11183–11194 (2021).

    Article  CAS  PubMed  Google Scholar 

  10. Valverde, R. Novo Nordisk – a focused healthcare company. Novo Nordisk https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/q4-2024-investor-presentation.pdf (2024).

  11. Petersen, J. et al. Nature 629, 1133–1141 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sass, F. et al. Nature 635, 987–1000 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Guglielmi, G. Nature 638, 591–592 (2025).

    Article  CAS  PubMed  Google Scholar 

  14. Drucker, D. J. Science 385, 258–260 (2024).

    Article  CAS  PubMed  Google Scholar 

  15. Ladebo, L. et al. Diabetes Care 47, 1834–1837 (2024).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This Comment emerged from discussions with key industrial, biotechnology and academic opinion leaders at the Novo Nordisk Foundation Center for Basal Metabolic Research Innovation Summit on Cardiometabolic Health held in Copenhagen, Denmark in 2024. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research centre, based at the University of Copenhagen, Denmark, and is partially funded by an unconditional donation from the Novo Nordisk Foundation (NNF23SA0084103).

Author information

Authors and Affiliations

  1. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Christoffer Clemmensen, Zachary Gerhart-Hines, Thue W. Schwartz, Juleen R. Zierath & Kei Sakamoto

  2. Department of Molecular Medicine and Surgery, Section for Integrative Physiology, Karolinska Institutet, Stockholm, Sweden

    Juleen R. Zierath

Authors
  1. Christoffer Clemmensen
    View author publications

    Search author on:PubMed Google Scholar

  2. Zachary Gerhart-Hines
    View author publications

    Search author on:PubMed Google Scholar

  3. Thue W. Schwartz
    View author publications

    Search author on:PubMed Google Scholar

  4. Juleen R. Zierath
    View author publications

    Search author on:PubMed Google Scholar

  5. Kei Sakamoto
    View author publications

    Search author on:PubMed Google Scholar

Contributions

All authors conceptualized the manuscript. C.C. led and drafted the manuscript. All authors provided critical feedback and edited the manuscript.

Corresponding author

Correspondence to Christoffer Clemmensen.

Ethics declarations

Competing interests

C.C. is a co-founder of Ousia Pharma, a biotechnology company developing therapeutics for the treatment of obesity. T.W.S. and Z.G.-H. are co-founders of Embark Laboratories and Incipiam Pharma, companies developing therapeutics for the treatment of type 2 diabetes and obesity. The remaining authors declare no competing interest.

Peer review

Peer review information

Nature Metabolism thanks Richard DiMarchi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Clemmensen, C., Gerhart-Hines, Z., Schwartz, T.W. et al. Shaping the future of cardiometabolic innovation: advances and opportunities. Nat Metab 7, 1495–1497 (2025). https://doi.org/10.1038/s42255-025-01343-5

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s42255-025-01343-5

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research